Dendreon Interest Remains Extremely High

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Since Dendreon (DNDN) has gotten a bit of life this week, there have been numerous inquiries as to "Where is this stock going?" from stock investors. 

There is obviously some hope by investors that the activists will be able to push the FDA into approving Provenge for late-stage prostate cancer.  The fact that an activist group has started Provengenow.org probably says it all.  It is not yet known who started Provengenow.org’s web site because the registrar is actually "MyPrivateRegistration" if you look up the domain owner.  This web site has actually become more full with more data even since yesterday.  What is becoming more obvious is that Dendreon "may" find itself as winner because of "cancer patient activism" rather than investor activism.  This activist group was also noted yesterday on CNBC and this helped the bullish scenario’s fight yesterday.

Do not interpret this as though we are saying this is going to occur, because we can’t and won’t say that.  What is obvious though is that speculators and investors are making bets on this daily. Shares are up 45% off of their recent lows put in after the FDA issued the approvable letter with a request for more data.  A 45% move is rarely just short covering and repositioning.  Dendreon shares are also up about 13% now from where they were at the $6.33 close the day that trading resumed from the disappointing FDA action (down from a $17.74 close the prior day).

Yesterday this rose on the AUA data that was new analysis on some older data, but we still have upcoming data presentations at the ASCO conference as well.  This is definitely one of the most unique stocks currently trading.  After looking at current options prices, it looks like options traders (selling the bets, static price only rather than floating) do not expect the stock to go over $8.00 nor below $6.40 over the next 3 weeks until the June options expire.

Jon C. Ogg
May 22, 2007

Jon Ogg can be reached at [email protected]; he does not own securities in the companies he covers.

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618